Avalo Therapeutics (NASDAQ:AVTX) Stock Price Up 7.9% – Time to Buy?

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) traded up 7.9% during mid-day trading on Friday . The company traded as high as $14.82 and last traded at $14.7450. 386,495 shares traded hands during mid-day trading, a decline of 64% from the average session volume of 1,087,490 shares. The stock had previously closed at $13.67.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Mizuho upped their price objective on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a research report on Thursday, May 14th. Weiss Ratings downgraded shares of Avalo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 26th. Wall Street Zen raised shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, March 29th. Piper Sandler reaffirmed an “overweight” rating and issued a $60.00 price objective (up from $48.00) on shares of Avalo Therapeutics in a research report on Monday, May 11th. Finally, BTIG Research upped their price objective on shares of Avalo Therapeutics from $40.00 to $58.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $46.67.

Avalo Therapeutics Price Performance

The stock has a market capitalization of $769.04 million, a PE ratio of -2.68 and a beta of 0.83. The stock’s 50 day simple moving average is $15.72 and its two-hundred day simple moving average is $16.22.

Avalo Therapeutics (NASDAQ:AVTX) last released its earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.02. As a group, equities research analysts predict that Avalo Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Avalo Therapeutics

In other Avalo Therapeutics news, insider Mittie Doyle sold 25,492 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $16.15, for a total value of $411,695.80. Following the transaction, the insider directly owned 3,622 shares in the company, valued at $58,495.30. The trade was a 87.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Paul Varki sold 75,063 shares of the business’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the completion of the transaction, the insider owned 3,634 shares in the company, valued at approximately $73,297.78. The trade was a 95.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 138,078 shares of company stock worth $2,501,346 over the last three months. 4.46% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS Group AG lifted its stake in shares of Avalo Therapeutics by 956.9% during the 4th quarter. UBS Group AG now owns 477,816 shares of the company’s stock valued at $8,677,000 after buying an additional 432,608 shares in the last quarter. Patient Square Capital LP purchased a new stake in shares of Avalo Therapeutics during the 3rd quarter valued at approximately $1,271,000. Moody Aldrich Partners LLC purchased a new stake in shares of Avalo Therapeutics during the 4th quarter valued at approximately $2,419,000. Cantor Fitzgerald L. P. purchased a new stake in shares of Avalo Therapeutics during the 3rd quarter valued at approximately $1,083,000. Finally, Boothbay Fund Management LLC lifted its stake in shares of Avalo Therapeutics by 1,916.6% during the 3rd quarter. Boothbay Fund Management LLC now owns 228,297 shares of the company’s stock valued at $2,902,000 after buying an additional 216,976 shares in the last quarter. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.